Multiple Myeloma Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple Myeloma pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Multiple Myeloma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Myeloma Market.

The Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Multiple Myeloma Pipeline Report: https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Multiple Myeloma treatment therapies with a considerable amount of success over the years.
• Multiple Myeloma companies working in the treatment market are Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, and others, are developing therapies for the Multiple Myeloma treatment
• Emerging Multiple Myeloma therapies in the different phases of clinical trials are- P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, and others are expected to have a significant impact on the Multiple Myeloma market in the coming years.
• In March 2025, The HealthTree Foundation has introduced an innovative AI-driven Personalized Clinical Trial Finder aimed at helping multiple myeloma (MM) patients identify appropriate clinical trials. Now integrated into the HealthTree Cure Hub Registry, this tool uses artificial intelligence to streamline and improve the matching process based on individual medical histories, enabling more accurate and efficient trial connections.
• In January 2025, Sanofi, a French pharmaceutical company, has announced the results of its Phase III IRAKLIA trial, which assessed Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM). The trial involved 531 adult patients with MM who had previously received at least one line of therapy, including lenalidomide and a proteasome inhibitor, across 252 global sites. The trial successfully met its co-primary endpoints when Sarclisa, administered subcutaneously via an on-body delivery system (OBDS), was combined with pomalidomide and dexamethasone (Pd).
• In September 2024, Johnson & Johnson announced results from the Phase III CARTITUDE-4 clinical trial, showing that CARVYKTI (ciltacabtagene autoleucel), its cell therapy, significantly improved overall survival in patients with multiple myeloma. The trial involved patients who had previously received at least one line of therapy, including a proteasome inhibitor (PI). CARVYKTI was compared to standard treatment regimens, including pomalidomide, bortezomib, and dexamethasone (PVd), or daratumumab, pomalidomide, and dexamethasone (DPd), in a randomized setting.
• In August 2024, Opna Bio, a Swiss biopharmaceutical company, has administered the first dose in a Phase I clinical trial of OPN-6602, an EP300/CBP bromodomain inhibitor intended for the treatment of multiple myeloma. The trial plans to enroll up to 130 participants with relapsed or refractory multiple myeloma at multiple locations across the U.S. The first dose was given at The START Center for Cancer Research in Grand Rapids, Michigan.
• In April 2024, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma® (idecabtagene vicleucel; ide-cel) for adults with relapsed or refractory multiple myeloma after at least two prior lines of therapy. These therapies must include an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody. This expanded approval, based on the KarMMa-3 trial, allows Abecma to be used earlier for patients exposed to all three treatment classes (triple-class exposed). Abecma is administered as a single infusion, with a newly recommended dose range of 300 to 510 x 106 CAR-positive T cells.

Multiple Myeloma Overview
Monoclonal immunoglobulin levels abnormally rise in multiple myeloma (MM), a clonal plasma cell proliferation condition. Uncontrolled synthesis of these plasma cells can eventually result in specific end-organ damage.

Get a Free Sample PDF Report to know more about Multiple Myeloma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:
• P-BCMACD19- ALLO1: Poseida Therapeutics
• ION251: Ionis Pharmaceuticals
• CID-103: CASI Pharmaceuticals
• STI-1492: Sorrento Therapeutics
• Descartes 08: Cartesian Therapeutics
• RAPA-201: Rapa Therapeutics
• PHE885: Novartis
• Venetoclax: AbbVie
• Elranatamab: Pfizer

Multiple Myeloma Route of Administration
Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Multiple Myeloma Molecule Type
Multiple Myeloma Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Multiple Myeloma Pipeline Therapeutics Assessment
• Multiple Myeloma Assessment by Product Type
• Multiple Myeloma By Stage and Product Type
• Multiple Myeloma Assessment by Route of Administration
• Multiple Myeloma By Stage and Route of Administration
• Multiple Myeloma Assessment by Molecule Type
• Multiple Myeloma by Stage and Molecule Type

DelveInsight's Multiple Myeloma Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Multiple Myeloma product details are provided in the report. Download the Multiple Myeloma pipeline report to learn more about the emerging Multiple Myeloma therapies at:
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Multiple Myeloma Therapeutics Market include:
Key companies developing therapies for Multiple Myeloma are - Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Sanofi S.A., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., Ltd., Novartis International, AGTeva Pharmaceutical Industries Ltd., Johnson and Johson, Inc. (Janssen Pharmaceuticals), AbbVie Inc., GlaxoSmithKline plc, Harpoon Therapeutics, and others.

Multiple Myeloma Pipeline Analysis:
The Multiple Myeloma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma Treatment.
• Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Multiple Myeloma drugs and therapies-
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Multiple Myeloma Pipeline Market Drivers
• Rising prevalence of multiple myeloma worldwide, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Multiple Myeloma Market.

Multiple Myeloma Pipeline Market Barriers
• However, high cost associated with the treatment of multiple myeloma, lack of healthcare infrastructure in developing economies and other factors are creating obstacles in the Multiple Myeloma Market growth.

Scope of Multiple Myeloma Pipeline Drug Insight
• Coverage: Global
• Key Multiple Myeloma Companies: Poseida Therapeutics, Ionis Pharmaceuticals, CASI Pharmaceuticals, Sorrento Therapeutics, Cartesian Therapeutics, Rapa Therapeutics, Novartis, AbbVie, Pfizer, and others
• Key Multiple Myeloma Therapies: P-BCMACD19- ALLO1, ION251, CID-103, STI-1492, Descartes 08, RAPA-201, PHE885, Venetoclax, Elranatamab, and others
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers

Request for Sample PDF Report for Multiple Myeloma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Multiple Myeloma Report Introduction
2. Multiple Myeloma Executive Summary
3. Multiple Myeloma Overview
4. Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment
5. Multiple Myeloma Pipeline Therapeutics
6. Multiple Myeloma Late Stage Products (Phase II/III)
7. Multiple Myeloma Mid Stage Products (Phase II)
8. Multiple Myeloma Early Stage Products (Phase I)
9. Multiple Myeloma Preclinical Stage Products
10. Multiple Myeloma Therapeutics Assessment
11. Multiple Myeloma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple Myeloma Key Companies
14. Multiple Myeloma Key Products
15. Multiple Myeloma Unmet Needs
16 . Multiple Myeloma Market Drivers and Barriers
17. Multiple Myeloma Future Perspectives and Conclusion
18. Multiple Myeloma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Multiple Myeloma Market
https://www.delveinsight.com/report-store/multiple-myeloma-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Multiple Myeloma Epidemiology https://www.delveinsight.com/report-store/multiple-myeloma-epidemiology-forecast-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Multiple Myeloma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market
• Antibody Drug Conjugate Market: https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
• Healthcare Competitive Benchmarking: https://www.delveinsight.com/consulting/competitive-benchmarking-services
• Tbi Market: https://www.delveinsight.com/report-store/traumatic-brain-injury-market
• Indwelling Catheters Market: https://www.delveinsight.com/report-store/indwelling-catheters-market
• Hyperlipidemia Market: https://www.delveinsight.com/report-store/hyperlipidemia-market
• Inflammatory Bowel Disease Market: https://www.delveinsight.com/report-store/crohns-disease-cd-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.